Brigham and Women's Hospital paid $10M over Harvard lab's fabricated heart-muscle data

Piero Anversa, a Harvard Medical School professor running the cardiac regeneration lab at Brigham and Women's Hospital, published a landmark 2001 paper claiming that transplanted stem cells could regrow damaged heart muscle in mice — a finding that reshaped how cardiologists thought about treating heart-attack damage and drew roughly $42 million in NIH grant funding to his lab over the following years.

Other labs repeatedly failed to reproduce the core finding. Harvard and the hospital opened a formal misconduct investigation in 2014 and concluded that a number of the lab's publications contained falsified or fabricated data and images.

In April 2017, Brigham and Women's Hospital and its parent, Partners HealthCare, agreed to pay $10 million to settle federal allegations that Anversa's lab had used manipulated data to obtain its NIH grants. Harvard and the hospital went on to request the retraction of more than 30 papers from the lab, and journals had pulled at least 14 by the end of 2018.

By the time the fraud came to light, the lab's claims had already helped justify a human clinical trial injecting cardiac stem cells into heart-attack patients; that trial was halted once the underlying research was found unreliable.

Fabricated data drew $42M in NIH funding and a $10M settlement, with 31 retractions, because the unreplicated 2001 result was never confirmed before a human trial.

A single influential 2001 result was never independently replicated before it became the basis for tens of millions of dollars in follow-on funding.

Data and images in the lab's publications were fabricated or manipulated, which only came to light after outside researchers' repeated failures to reproduce the core finding forced an investigation.

The unreplicated finding was allowed to justify moving into a human clinical trial before its scientific basis had actually been confirmed.

Institutional oversight caught the problem only after years of grant funding and one launched clinical trial, not before either.

A result that redirects a field needs independent replication before it funds more research and a human trial — the harder a claim is to reproduce, the more scrutiny it deserves, not less.

The cardiac stem cell trial built on Anversa's work was halted, and the c-kit stem cell theory it was based on lost credibility across the field. The case became a standard reference in research-integrity training for how unreplicated results can compound into years of downstream funding and harm before anyone checks.